Assignee
IMMUNOCORE LTD
GB·35 granted patents·95 pending applications·418 citations·filing 2003–2025
Top patents by PatentIndex Score
130 records- 0196US8361794B2Cells expressing a modified T cell receptorIMMUNOCORE LTD·Filed 2005·Granted Jan 29, 2013·47 cites·25 claims
- 0295US8367804B2High affinity NY-ESO T cell receptorsIMMUNOCORE LTD·Filed 2011·Granted Feb 5, 2013·20 cites·4 claims
- 0394US8008438B2High affinity NY-ESO T cell receptorsIMMUNOCORE LTD·Filed 2010·Granted Aug 30, 2011·11 cites·2 claims
- 0494US7608410B2Method of improving T cell receptorsIMMUNOCORE LTD·Filed 2008·Granted Oct 27, 2009·51 cites·13 claims
- 0593US11427624B2T cell receptorsIMMUNOCORE LTD·Filed 2021·Granted Aug 30, 2022·11 cites·11 claims
- 0693US7763718B2Soluble T cell receptorsIMMUNOCORE LTD·Filed 2007·Granted Jul 27, 2010·33 cites·9 claims
- 0793US7666604B2Modified soluble T cell receptorIMMUNOCORE LTD·Filed 2003·Granted Feb 23, 2010·77 cites·19 claims
- 0893US7569664B2Single chain recombinant T cell receptorsIMMUNOCORE LTD·Filed 2003·Granted Aug 4, 2009·78 cites·27 claims
- 0992US10517960B2Bifunctional polypeptidesIMMUNOCORE LTD·Filed 2019·Granted Dec 31, 2019·9 cites·6 claims
- 1089US12018062B2T cell receptorsIMMUNOCORE LTD·Filed 2023·Granted Jun 25, 2024·1 cites·22 claims
- 1189US9068178B2Nucleic acid molecules encoding non-naturally occurring T cell receptors and cells thereofIMMUNOCORE LTD·Filed 2013·Granted Jun 30, 2015·11 cites·66 claims
- 1288US9255135B2High affinity HIV T cell receptorsIMMUNOCORE LTD·Filed 2013·Granted Feb 9, 2016·5 cites·19 claims
- 1387US12134647B2Binding moleculesIMMUNOCORE LTD·Filed 2024·Granted Nov 5, 2024·3 cites·22 claims
- 1487US11017882B2Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complexIMMUNOCORE LTD·Filed 2015·Granted May 25, 2021·6 cites·13 claims
- 1587US8378074B2High affinity HIV T cell receptorsIMMUNOCORE LTD·Filed 2006·Granted Feb 19, 2013·9 cites·24 claims
- 1686US11505590B2T cell receptorsIMMUNOCORE LTD·Filed 2017·Granted Nov 22, 2022·10 cites·45 claims
- 1785US12065475B2T cell receptors and fusion proteins thereofIMMUNOCORE LTD·Filed 2023·Granted Aug 20, 2024·3 cites·21 claims
- 1885US11718657B2T cell receptorsIMMUNOCORE LTD·Filed 2018·Granted Aug 8, 2023·4 cites·17 claims
- 1984US12195534B2Binding moleculesIMMUNOCORE LTD·Filed 2024·Granted Jan 14, 2025·2 cites·22 claims
- 2084US11929151B2Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complexIMMUNOCORE LTD·Filed 2021·Granted Mar 12, 2024·1 cites·13 claims
- 2184US8017730B2T cell receptors which specifically bind to VYGFVRACL-HLA-A24IMMUNOCORE LTD·Filed 2006·Granted Sep 13, 2011·5 cites·1 claims
- 2283US10576162B2Bifunctional polypeptidesIMMUNOCORE LTD·Filed 2019·Granted Mar 3, 2020·2 cites·2 claims
- 2383US9115372B2Cells expressing modified T cell receptorIMMUNOCORE LTD·Filed 2012·Granted Aug 25, 2015·5 cites·20 claims
- 2481US12103971B2HIV specific binding moleculesIMMUNOCORE LTD·Filed 2022·Granted Oct 1, 2024·2 cites·16 claims
- 2581US2023241238A1Bifunctional polypeptidesIMMUNOCORE LTD·Filed 2022·Application pending·0 cites
- 2680US2024368243A1T Cell ReceptorsIMMUNOCORE LTD·Filed 2024·Application pending·0 cites
- 2780US2024312566A1Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complexIMMUNOCORE LTD·Filed 2024·Application pending·0 cites
- 2879US10420846B2Bifunctional polypeptidesIMMUNOCORE LTD·Filed 2019·Granted Sep 24, 2019·1 cites·5 claims
- 2978US11639374B2T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complexIMMUNOCORE LTD·Filed 2016·Granted May 2, 2023·6 cites·14 claims
- 3078US2025134956A1Peptides derived from kita-kyushu lung cancer antigen (kklc1, ct83, cxorf61) and complexes comprising such peptides bound to mhc moleculesIMMUNOCORE LTD·Filed 2024·Application pending·0 cites
- 3175US11440944B2Engineered immune-mobilizing T-cell receptors with enhanced affinity for HIV-1 GagIMMUNOCORE LTD·Filed 2017·Granted Sep 13, 2022·1 cites·10 claims
- 3274US11827688B2Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion proteinIMMUNOCORE LTD·Filed 2017·Granted Nov 28, 2023·2 cites·14 claims
- 3373US10835577B2Peptides derived from Kita-kyushu lung cancer antigen (KKLC1, CT83, CXorf61) and complexes comprising such peptides bound to MHC moleculesIMMUNOCORE LTD·Filed 2016·Granted Nov 17, 2020·1 cites·10 claims
- 3470US2023330181A1Peptides derived from kita-kyushu lung cancer antigen (kklc1, ct83, cxorf61) and complexes comprising such peptides bound to mhc moleculesIMMUNOCORE LTD·Filed 2023·Application pending·0 cites
- 3569US2025026829A1Binding moleculesIMMUNOCORE LTD·Filed 2024·Application pending·0 cites
- 3667US2023192806A1Engineered immune-mobilizing t-cell receptors with enhanced affinity for hiv-1 gagIMMUNOCORE LTD·Filed 2022·Application pending·0 cites
- 3766US2024052011A1Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion proteinIMMUNOCORE LTD·Filed 2023·Application pending·0 cites
- 3866US2025179178A1Binding moleculesIMMUNOCORE LTD·Filed 2024·Application pending·0 cites
- 3966US2022235113A1TCR LibrariesIMMUNOCORE LTD·Filed 2022·Application pending·0 cites
- 4066US2024301027A1Treatment of mage-a4 positive cancerIMMUNOCORE LTD·Filed 2024·Application pending·0 cites
- 4165US10851366B2Peptides derived from Lengsin (LGSN), complexes comprising such peptides bound to MHC moleculesIMMUNOCORE LTD·Filed 2016·Granted Dec 1, 2020·1 cites·10 claims
- 4264US2019247512A1Bifunctional polypeptidesIMMUNOCORE LTD·Filed 2018·Application pending·0 cites
- 4363US2024092859A1T cell receptors and fusion proteins thereofIMMUNOCORE LTD·Filed 2023·Application pending·0 cites
- 4463US2021371493A1Tcr librariesIMMUNOCORE LTD·Filed 2021·Application pending·0 cites
- 4563US2023190901A1Peptides derived from melanoma-associated antigen c2 (magec2) and uses thereofIMMUNOCORE LTD·Filed 2022·Application pending·0 cites
- 4662US2021061874A1Claudin-6 peptidesIMMUNOCORE LTD·Filed 2020·Application pending·0 cites
- 4761US2021121526A1Peptides derived from kita-kyushu lung cancer antigen (kklc1, ct83, cxorf61) and complexes comprising such peptides bound to mhc moleculesIMMUNOCORE LTD·Filed 2020·Application pending·0 cites
- 4861US2021322528A1Peptides from npsr1IMMUNOCORE LTD·Filed 2021·Application pending·0 cites
- 4960US2025333504A1TreatmentIMMUNOCORE LTD·Filed 2022·Application pending·0 cites
- 5058US11739441B2TCR librariesIMMUNOCORE LTD·Filed 2021·Granted Aug 29, 2023·0 cites·1 claims
Showing the top 50 of 130 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when IMMUNOCORE LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →